Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Int J Radiat Oncol Biol Phys ; 36(5): 1137-45, 1996 Dec 01.
Article in English | MEDLINE | ID: mdl-8985036

ABSTRACT

PURPOSE: A Phase II multicenter trial testing an accelerated regimen of radiotherapy in locally advanced and inoperable cancers of the head and neck, in patients selected on the basis of 5-bromo-2-deoxyuridine/DNA flow cytometry-derived tumor potential doubling time (Tpot). METHODS AND MATERIALS: From September 1992 to September 1993, 23 patients consecutively diagnosed to have locally advanced, inoperable carcinomas of the oral cavity and the oropharynx, with Tpot of < or = 5 days, received an accelerated radiotherapy regimen (AF) based on a modification of the concomitant boost technique: 2 Gy/fraction once a day, delivered 5 days a week up to 26 Gy, followed by 2 Gy/fraction twice a day, with a 6-h interval, one of the two fractions being delivered as a concomitant boost to reduced fields, up to 66 Gy total dose (off-cord reduction at 46 Gy), shortening the overall treatment time to 4.5 weeks. A contemporary control group of 46 patients with Tpot of >5 days or unknown was treated with conventional fractionation (CF): 2 Gy/fraction once a day, 5 days a week, up to 66 Gy in 6.5 weeks, with fields shrinkage after 46 Gy. RESULTS: All patients completed the accelerated regimen according to protocol and in the prescribed overall treatment time. Immediate tolerance was fairly good: 65% of the patients in the AF group experienced Grade 3 mucositis vs. 45% in the CF group (p = n.s.). Symptoms related to mucosal reactions seemed to persist longer in AF than in CF patients. The crude proportion of mild (Grades 1 and 2) late effects on skin (p < 0.01) and salivary glands (p < 0.05) was higher in AF than in CF patients, although these reactions did not exceed the limits of tolerance. Three patients in the AF and 1 in the CF arm experienced a late Grade 4 bone complication. Actuarial estimates of severe (Grades 3 and 4) late complications showed a 2-year hazard of 33.3% in the AF arm and 49.7% in CF (p = NS). The actuarial 2-year local control rate of the AF patients was 49.4%, while actuarial 2-year overall survival for the same patients was 43.5%. CONCLUSION: The results suggested that this accelerated regimen is worth testing in a controlled randomized trial to compare different accelerated schedules. Our findings also confirmed the 5-bromo-2-deoxyuridine/DNA flow cytometry technique as a suitable method of evaluating tumor cell kinetics in multicenter clinical studies, on condition that all measurements are carried out by one most experienced laboratory.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Mouth Neoplasms/radiotherapy , Oropharyngeal Neoplasms/radiotherapy , Adult , Aged , Bromodeoxyuridine/metabolism , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/pathology , Cause of Death , DNA/biosynthesis , Female , Humans , Male , Middle Aged , Mouth Neoplasms/mortality , Mouth Neoplasms/pathology , Oropharyngeal Neoplasms/mortality , Oropharyngeal Neoplasms/pathology , Survival Rate
3.
Acta Otorhinolaryngol Ital ; 16(5): 428-32, 1996 Oct.
Article in Italian | MEDLINE | ID: mdl-9199087

ABSTRACT

The present work analyzes the clinical results obtained at the Istituto del Radio in Brescia, Italy, using radiotherapy in the treatment of T2N0 glottic carcinomas. The analysis covers a sampling of 127 patients who had been treated using fixed field with 60Co or linear accelerator (high energy photons) technique delivering a minimum target dose of 60 Gy over the course of a 6-week period; 200 cGy a day. The purpose of the present study was to evaluate: treatment response 3 months after treatment was suspended using the WHO nomenclature; Overall Survival Rate and Actuarial Disease-Free Survival Rate at five and ten years from the end of treatment comparing the results obtained in cases of T2a and T2b; biological cost of treatment in terms of late recurrences. Three months after treatment had ended, a complete response was seen in 95% of the patients. The overall survival was 85% at five years while the NED survival was 67% at five years. Surgical salvage made it possible to treat 44% of those who did not respond to radiotherapy or who had a recurrence. Late recurrence rate was 4.7%. The clinical results are slightly lower than those obtained in the literature for surgical series in terms of survival probability. They were, however, certainly better in terms of good vocal preservation.


Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Glottis/radiation effects , Laryngeal Neoplasms/radiotherapy , Carcinoma, Squamous Cell/pathology , Carcinoma, Squamous Cell/surgery , Combined Modality Therapy , Female , Glottis/pathology , Glottis/surgery , Humans , Laryngeal Neoplasms/pathology , Laryngeal Neoplasms/surgery , Male , Neoplasm Recurrence, Local , Neoplasm Staging , Radiation Dosage , Retrospective Studies , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...